Global Medical Device Regulatory Strategy: 40+ Statistics 2026

VelSafe Insights

Global Regulatory Strategy for Medical Device Manufacturers: 40+ Statistics on QMSR, EU MDR, EUDAMED, and AI Devices Through 2026

The global medical devices market reached $623 billion in 2026, on a trajectory to $1.08 trillion by 2035. Three regulatory milestones converged in early 2026 that fundamentally reshape how manufacturers access major markets: FDA’s Quality Management System Regulation (QMSR) took effect February 2, 2026, replacing the QSR with ISO 13485:2016 by reference; EUDAMED became mandatory for all EU economic operators on May 28, 2026, with notified bodies reporting 12-18 month backlogs; and FDA has cleared over 1,000 AI/ML medical devices – 295 in 2025 alone – with EU AI Act high-risk obligations effective August 2026-2027 adding another regulatory layer. This article compiles 40+ statistics on the regulatory landscape every medical device manufacturer must navigate to compete globally in 2026 and beyond.

40+ Statistics

QMSR Feb 2026

EUDAMED May 2026

AI Device Clearances 2025-26

Editor's Choice: Key Global Regulatory Statistics for Medical Device Manufacturers

$623B

Global medical devices market in 2026, projected to reach $1.08 trillion by 2035 at 6.34% CAGR – the addressable market that global regulatory strategy is designed to access

Toward Healthcare / Market Research Future, 2026

Feb 2, 2026

FDA QMSR effective date – replacing the QSR with ISO 13485:2016 by reference in 21 CFR Part 820. All FDA inspections now conducted under new Compliance Program 7382.850. QSIT withdrawn.

FDA.gov; Federal Register December 2025

12-18 mo

Current EU notified body backlog for MDR technical file reviews. Manufacturers who have not yet submitted face serious risk of missing the Class IIa/IIb December 2028 and Class III/implantable IIb December 2027 deadlines

NordMDR / EU MDR Compliance Timeline, May 2026

In the span of four months in early 2026, two of the world’s three largest medical device regulatory frameworks reached major enforcement milestones simultaneously. On February 2, 2026, FDA’s Quality Management System Regulation (QMSR) took effect, ending the Quality System Regulation (QSR) that had governed U.S. device manufacturing compliance since 1996 and replacing it with a regulation that incorporates ISO 13485:2016 by reference. FDA immediately stopped using QSIT for inspections and began using a new inspection process under Compliance Program 7382.850. On May 28, 2026, EUDAMED registration became mandatory for every entity in the EU medical device supply chain, with no registration meaning no legal EU market access, effective immediately and without a grace period.

These simultaneous milestones, combined with the FDA’s record-pace clearance of AI/ML medical devices (1,000+ cleared through early 2026, 295 in 2025 alone) and the EU AI Act’s high-risk device obligations phasing in between August 2026 and 2027, define the global regulatory strategy landscape that medical device manufacturers must navigate to remain competitive. This article compiles 40+ statistics on the QMSR transition, EU MDR/EUDAMED compliance, AI device regulation, go-to-market sequencing, and the specific 2026-2028 deadline framework that determines market access.

1. FDA QMSR: What Changed on February 2, 2026, and What It Means for Manufacturers

179 CFR sections

Amended across 18 parts of Title 21 in the QMSR technical amendments published December 4, 2025 – updating references from QSR to QMSR across the entire FDA regulatory apparatus, not just Part 820. Federal Register, December 4, 2025

1,000+

AI/ML medical devices cleared or approved by FDA through early 2026 – with 95-97% going through 510(k) rather than De Novo or PMA. 295 new authorizations in 2025 alone. FDA; Censinet, June 2026; IntuitionLabs, March 2026

May 28, 2026

EUDAMED mandatory use date for all four validated modules (Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, Market Surveillance). No registration = no EU market access from this date. No grace period. Commission Decision EU 2025/2371; NordMDR, May 2026

$13.67B to $255.76B

AI-enabled medical devices market growth trajectory – from $13.67B in 2024 to $255.76B by 2033 at 38.5% CAGR. North America holds 52.86% of current market. Software dominates at 51.15% revenue share. Grand View Research, 2026

142 days

Median time to 510(k) clearance for AI/ML SaMD in 2025 (average 150 days), with 25% of devices cleared in under 90 days – demonstrating rapid path to market for well-prepared submissions. Innolitics 2025 Year in Review, December 2025

26.4%

European medical technology market share of the global market – a $170 billion market (2024) that is the second-largest device market after the U.S. (46.4%). Mandatory EUDAMED compliance is now the price of admission. Arena Solutions, December 2025

QMSR vs. QSR: The Key Changes in 21 CFR Part 820

QSR (pre Feb 2, 2026)

FDA-specific QMS requirements in 21 CFR Part 820. Not formally harmonized with international standards. QSIT inspection technique. Management review, quality audits, and supplier audit reports could be withheld under 820.180(c) exceptions.

QMSR (from Feb 2, 2026)

ISO 13485:2016 and ISO 9000:2015 Clause 3 incorporated by reference – having the force of law in Part 820. New Compliance Program 7382.850 inspection process. No 820.180(c) exceptions: FDA may now inspect management review, quality audits, and supplier audit reports. Risk-based thinking required across all QMS processes.

Documentation shift

DMR/DHF/DHR unified into Medical Device File (MDF) structure per ISO 13485. Manufacturers must demonstrate that records created before Feb 2, 2026 meet QMSR requirements through comparative analysis. No transition grace period – full compliance required from Feb 2, 2026.

What did NOT change

QSR and QMSR requirements are “substantially similar” per FDA preamble – manufacturers already ISO 13485-certified face primarily documentation alignment work. Humanitarian Device Exemption and PMA submissions received after Feb 2 must demonstrate QMSR compliance, not QSR compliance.

Sources: FDA.gov QMSR FAQ; Federal Register December 4, 2025; ComplianceQuest April 2026; Morgan Lewis October 2024; Alston & Bird November 2025

The QMSR final rule was issued February 2, 2024, and became effective February 2, 2026, after a two-year transition period. FDA provided no additional grace period – full compliance with QMSR was required from the effective date. PMA and HDE applications received after February 2, 2026 must demonstrate QMSR compliance; applications received before that date under QSR requirements are evaluated under the QSR. FDA QMSR FAQ; Morgan Lewis, October 2024
QMSR represents the most significant change to U.S. medical device quality compliance in nearly three decades. The critical compliance shift from the manufacturer’s perspective: risk-based thinking is no longer confined to design controls. Under QMSR, FDA expects risk-based decision-making to be embedded in day-to-day operations, supplier management, software validation, production controls, change management, complaint handling, CAPA, and management review – and those risk-based decisions must be provable through documented evidence. ComplianceQuest, April 2026
On February 2, 2026, FDA simultaneously withdrew QSIT (Quality System Inspection Technique) and the documents governing the prior inspection process (7382.845 and 7383.001). All FDA inspections are now conducted under the new Compliance Program 7382.850. The 820.180(c) exceptions that previously allowed manufacturers to withhold management review records and quality audit reports from FDA inspectors are no longer operative under QMSR. FDA.gov; Federal Register, December 4, 2025
A QMSR-specific complication for premarket submissions: FDA issued a draft guidance on October 27, 2025 describing QMS information expected in PMA and HDE submissions under QMSR. This draft guidance, cited by Alston and Bird (November 2025), signals that FDA expects manufacturers to identify gaps early, document risk-based rationales clearly, and foster structured collaboration across internal and external teams in preparation for submissions under the new framework. FDA draft guidance, October 27, 2025; Alston and Bird, November 2025
Manufacturers already certified to ISO 13485 faced primarily documentation alignment work in the QMSR transition. Manufacturers who were compliant with QSR but not ISO 13485 faced substantially more change – particularly in risk management integration, supplier controls, and the shift from DMR/DHF/DHR documentation to the Medical Device File structure. The QMSR technical amendments published December 4, 2025 updated 179 sections across 18 parts of Title 21, reflecting the scope of the regulatory apparatus that needed to align with the new standard. Federal Register, December 4, 2025; Complizen, May 2026

2. EU MDR and EUDAMED: The May 2026 Mandatory Use Date and the Notified Body Crunch

EUDAMED Mandatory: May 28, 2026

Commission Decision (EU) 2025/2371 published November 27, 2025 validated four EUDAMED modules and triggered a six-month transition. From May 28, 2026: every manufacturer, EU Authorized Representative, importer, and distributor without a valid SRN (Single Registration Number) cannot legally place devices on the EU market. No warning letters, no grace period per NordMDR analysis. Legacy device registration deadline: November 27, 2026.

Notified Body Backlog: 12-18 Months

Notified Bodies are currently reporting 12-18 month backlogs for MDR technical file reviews. Class IIa, IIb, and III manufacturers who have not yet submitted to a Notified Body are at serious risk of missing the December 2027 (Class III and implantable IIb) and December 2028 (Class IIa and non-implantable IIb) deadlines. Notified Body slots are fully booked 12-18 months in advance.

Four EUDAMED Modules Now Mandatory

The four validated modules: Actor Registration (SRN assignment), UDI/Device Registration (product-level traceability), Notified Bodies and Certificates (conformity assessment records), and Market Surveillance (competent authority safety actions). Vigilance/PMS modules remain in development.

The European medical technology market was estimated at approximately $170 billion in 2024, representing 26.4% of the global medical device market – second only to the U.S. at 46.4%. The top five EU markets are Germany, France, the United Kingdom, Italy, and Spain. EUDAMED compliance is now the operational entry condition for participating in this market. Arena Solutions, December 2025
For non-EU manufacturers, EUDAMED compliance requires appointing an EU Authorized Representative (EU AR) – a legal entity established in the EU who registers with EUDAMED on the manufacturer’s behalf, holds a valid SRN, and assumes co-responsibility for EUDAMED data accuracy. Arnold and Porter (February 2026) explicitly flags this: “failure to plan early for notified body engagement and certificate renewals can result in missed market opportunities.” Arnold and Porter, February 2026
The MDR deadline framework for device class compliance: Class III and implantable Class IIb devices must hold a valid MDR certificate from a Notified Body by December 2027. Class IIa and non-implantable Class IIb transition must be complete by December 2028. Class I devices requiring a Notified Body (sterile, measuring, reusable surgical instruments) have their own timelines. With 12-18 month backlogs, manufacturers who have not yet submitted are at concrete risk of missing these mandatory windows. NordMDR, May 2026
The UDI obligation compounds the EUDAMED registration requirement. For new MDR-compliant devices placed on the EU market on or after May 2026’s mandatory EUDAMED date, UDI/device registration must be completed before the device may be placed on the market. For legacy devices already on the market, manufacturers have until November 27, 2026 to complete registration – or the device must be withdrawn. Arena Solutions, December 2025; MDX CRO, June 2026
The December 12, 2025 European Commission proposal introduced a draft Implementing Regulation to standardize quality management and procedural protocols for notified bodies under the MDR and IVDR – directly addressing the transparency and variability concerns raised by manufacturers navigating the NB selection and engagement process. This proposal signals continued EU regulatory evolution and adds another tracking obligation to the global regulatory calendar. Arnold and Porter, February 2026
Article 10a (effective January 2025, introduced by Regulation EU 2024/1860) introduces a mandatory supply interruption notification obligation: manufacturers must notify authorities, economic operators, and health institutions of any interruption or discontinuation of supply that could result in serious harm. Failure to notify about an unavailable device registered as “On the Market” in EUDAMED may lead to double liability. This provision links EUDAMED data accuracy directly to supply chain legal exposure. Celegence, December 2025

3. AI/ML Medical Devices: 1,000+ Cleared, 295 in 2025, and Two New Regulatory Layers

1,000+

FDA AI/ML device clearances/approvals through early 2026 – 95-97% via 510(k)

Censinet, June 2026

295

New AI/ML device authorizations in 2025 alone; 24 cleared in March 2026 alone (one every 31 hours)

IntuitionLabs; Innolitics, 2026

142 days

Median 510(k) clearance time for AI/ML SaMD in 2025; 25% cleared under 90 days

Innolitics, December 2025

38.5% CAGR

AI-enabled device market growth 2025-2033: $13.67B (2024) to $255.76B (2033)

Grand View Research, 2026

FDA cleared or approved over 1,000 AI/ML medical devices through early 2026, with 95-97% going through the 510(k) pathway. Radiology has consistently dominated AI clearances – accounting for approximately 75% of 2025 AI/ML 510(k) entries – but April 2026 data shows radiology’s share dropping from 79% to 56% as AI expands into cardiology, pathology, and other specialties. GE HealthCare topped FDA’s AI-enabled device authorization list for the fourth year running as of July 2025, with 100 listed authorizations. IntuitionLabs, March 2026; Censinet, June 2026; Innolitics, 2026
FDA’s January 2025 draft guidance on AI-Enabled Device Software Functions introduced the Predetermined Change Control Plan (PCCP) – a mechanism that allows manufacturers to pre-specify anticipated algorithm changes and validation methods, avoiding the need to file a new 510(k) every time the model is retrained. As of 2025, PCCPs were included in approximately 10% of AI/ML 510(k) submissions. Censinet, June 2026; IntuitionLabs, March 2026
Manufacturers pursuing AI device clearances face two converging regulatory layers in 2026-2027: FDA’s evolving AI/ML device framework under the 510(k) pathway, and the EU AI Act’s high-risk device obligations, which begin phasing in August 2026 and run through 2027. An AI-enabled medical device classified as high-risk under the EU AI Act must comply with both the EU MDR (CE marking) and EU AI Act (Annex III conformity assessment) requirements – adding a second conformity assessment obligation that does not exist for non-AI devices. IntuitionLabs, April 2026
AI device safety monitoring is emerging as a gap. By mid-2025, only approximately 5% of FDA-cleared AI devices had reported adverse event data (including device malfunctions and one death). IntuitionLabs notes that post-market monitoring is still lagging behind the pace of clearances – a pattern that regulators in both the U.S. and EU are expected to address through strengthened post-market surveillance requirements. IntuitionLabs, April 2026
The AI-enabled medical devices market was valued at $13.67 billion in 2024 and is projected to reach $255.76 billion by 2033 at 38.5% CAGR. North America holds 52.86% of the current market; Asia Pacific is the fastest-growing at 40.84% CAGR. Software dominates at 51.15% revenue share, with radiology representing the largest therapeutic area. Grand View Research, 2026

4. Market Size and Go-to-Market Sequencing: The $623B Opportunity and Three Entry Models

Model 1: U.S. First

Submit FDA 510(k) or PMA first; use the cleared 510(k) substantial equivalence as a component in subsequent EU/other submissions. Advantages: U.S. is the largest single market (46.4% global share); FDA clearance generates the clinical and technical evidence base used in EU dossiers. Risk: EU MDR’s performance requirements may differ substantially from FDA’s 510(k) substantial equivalence standard – EU submission is not simply a translation of the 510(k).

Model 2: EU First

Pursue CE mark first where EU clinical requirements are more demanding than FDA’s, generating the clinical evidence base that also satisfies FDA requirements. Risk in 2026: notified body 12-18 month backlogs make EU first an increasingly delayed strategy. Class IIb and III manufacturers face December 2027 hard deadlines. Not recommended for companies that have not already engaged a notified body.

Model 3: Parallel / Staggered

Develop a single unified technical dossier meeting the requirements of both FDA and EU MDR simultaneously; submit to both jurisdictions in close succession (staggered) rather than sequentially. The highest upfront design and regulatory investment but shortest time to global market access. Recommended for Class II/Class IIa devices where the submission requirements overlap most significantly.

The global medical devices market reached an estimated $623.37 billion in 2026 and is projected to reach $1.08 trillion by 2035 at a 6.34% CAGR. The U.S. (46.4% global share) and EU (26.4% global share) together account for nearly three-quarters of the global market – making effective simultaneous access to both markets the single highest-value regulatory strategy objective for most device manufacturers. Toward Healthcare; Market Research Future, 2026
The QMSR transition creates a strategic harmonization opportunity: manufacturers already ISO 13485-certified now hold a QMS framework that simultaneously satisfies FDA’s QMSR (via ISO 13485:2016 incorporation by reference) and EU MDR’s quality system requirements (which reference ISO 13485 directly). A single ISO 13485-compliant QMS now genuinely serves both major regulatory frameworks, reducing the QMS compliance overhead that previously differed between U.S. and EU requirements. ComplianceQuest, April 2026; FDA.gov
For emerging market entry, Arnold and Porter (February 2026) identifies a new dynamic in 2025-2026: “The complexity and cost of compliance have led some companies to reconsider EU launches altogether.” This represents a meaningful market access decision signal – companies that cannot afford the notified body engagement timeline and cost for EU MDR compliance are prioritizing other market entry strategies. For competitors who do complete EU MDR certification, the notified body backlog effectively creates a regulatory moat. Arnold and Porter, February 2026
For the U.S. specifically: FDA cleared around 1,000 AI-powered medical devices from 1995 through August 2024, with the pace accelerating significantly in recent years (295 in 2025 alone). The 510(k) median clearance time for AI/ML SaMD in 2025 was 142 days, with 25% cleared in under 90 days. This pace creates a competitive dynamic where well-prepared submissions achieve market access significantly faster than poorly prepared ones – turning regulatory submission quality into a competitive differentiator. Innolitics, December 2025; Toward Healthcare, 2026

5. Post-Market Surveillance: The Expanding Obligation Across All Major Jurisdictions

EU MDR Article 10a – mandatory supply interruption notification (from January 2025)

FDA QMSR – management review and quality audit reports now fully accessible to inspectors

EU MDR EUDAMED Market Surveillance module – competent authority safety action data

AI/ML devices – only ~5% of cleared devices had reported adverse event data by mid-2025

PCCP – Predetermined Change Control Plans now in 10% of AI/ML 510(k) submissions

Post-market surveillance obligations have expanded materially on both sides of the Atlantic in 2025-2026. Under QMSR, FDA’s removal of the 820.180(c) exceptions means that management review records, quality audit reports, and supplier audit reports that were previously shielded from FDA inspection can now be requested and reviewed during device manufacturer inspections. This fundamentally changes what manufacturers must be prepared to show during an FDA inspection. FDA QMSR FAQ; ComplianceQuest, April 2026
EU MDR’s post-market framework through EUDAMED adds a transparency dimension that is new to most manufacturers: the Market Surveillance module allows EU competent authorities to access real-time device registration, certificate, and incident data. Manufacturers whose EUDAMED data is inaccurate, outdated, or inconsistent with physical product in the market create regulatory exposure through the database itself – independent of product performance. Celegence, December 2025; QServe Group, February 2026
For AI/ML devices specifically, the PCCP (Predetermined Change Control Plan) mechanism introduced in FDA’s January 2025 draft guidance is the primary tool for managing post-market algorithm changes without continuous 510(k) resubmission. PCCPs specify in advance which algorithm changes are anticipated, how they will be validated, and what performance thresholds must be maintained. Manufacturers developing AI devices who build PCCP frameworks into their initial submissions are positioning their products for faster post-market iteration than competitors who treat the initial clearance as a static endpoint. Censinet, June 2026
Arnold and Porter (February 2026) identifies a cross-jurisdictional theme: “Every major jurisdiction is strengthening post-market surveillance, clinical follow-up, and real-world evidence requirements. Lifecycle regulation is replacing pre-market approval as the primary risk management framework.” For device manufacturers, this means that regulatory investment does not end at clearance – it becomes an ongoing operational cost with specific reporting, monitoring, and evidence generation obligations that must be resourced and budgeted throughout the device’s commercial life. Arnold and Porter, February 2026

6. Emerging Market Regulatory Trends: Formalization Beyond the U.S. and EU

IMDRF Convergence

The International Medical Device Regulators Forum (IMDRF) framework is driving regulatory convergence across Canada (MDEL/MDL), Australia (TGA), Japan (PMDA), Brazil (ANVISA), and South Korea (MFDS). Manufacturers investing in IMDRF-harmonized technical documentation are building dossiers that can be adapted across multiple jurisdictions rather than rebuilt from scratch for each market.

Asia Pacific Acceleration

Asia Pacific is the fastest-growing AI-enabled medical device market at 40.84% CAGR. Japan’s PMDA has been a consistent early adopter of IMDRF principles. China’s NMPA has implemented its own registration requirements. The Asia Pacific region requires jurisdiction-specific regulatory strategy beyond IMDRF convergence for the largest individual markets.

Formalizing Markets

Markets previously operating with informal device oversight are formalizing requirements. Botswana introduced phased mandatory device registration from April 2026. Oman introduced new high-risk device requirements. These markets – individually small but collectively significant across Africa, the Middle East, and Southeast Asia – are implementing registration frameworks that require regulatory affairs resources to monitor and respond to.

The medical devices market outside the U.S. and EU is growing rapidly. Asia Pacific’s AI-enabled device market is growing at 40.84% CAGR – faster than any other region and faster than the global average of 38.5%. For manufacturers with AI device portfolios, the regulatory strategy for Asia Pacific market access is becoming a near-term commercial priority, not a long-term consideration. Grand View Research, 2026
IMDRF convergence creates a multiplier effect for regulatory investment: a technical dossier structured to IMDRF principles can serve as the foundation for submissions in Canada, Australia, Japan, Brazil, and South Korea with jurisdiction-specific adaptations rather than complete rebuilds. For manufacturers who build IMDRF-aligned documentation from the design stage, the marginal cost of entering each additional IMDRF-aligned market is substantially lower than for manufacturers who build jurisdiction-specific submissions sequentially. global regulatory strategy framework; IMDRF
The QMS harmonization benefit created by QMSR is specifically relevant for global market access: ISO 13485 certification is accepted as the QMS evidence base by regulatory authorities in the EU, Canada (under MDSAP), Australia, Japan, Brazil, and the U.S. (through QMSR’s ISO 13485 incorporation). A single ISO 13485-compliant QMS with MDSAP audit coverage provides quality system evidence for all five MDSAP member jurisdictions simultaneously – eliminating the need for jurisdiction-specific QMS audits in each market. MDSAP framework; FDA.gov

7. The 2026-2028 Regulatory Calendar: Deadlines That Determine Market Access

Critical 2026-2028 Deadlines for Global Medical Device Market Access

Feb 2, 2026 – PASSED

FDA QMSR effective. All FDA device manufacturer inspections now under new CP 7382.850. QSR withdrawn. PMA/HDE submissions must demonstrate QMSR compliance.

May 28, 2026 – PASSED

EUDAMED mandatory for all EU economic operators. No SRN = no EU market access. Immediate enforcement, no grace period. Actor registration, UDI/Device, NB Certificates, Market Surveillance modules all active.

Aug-Dec 2026

EU AI Act high-risk device obligations begin phasing in. Class IIa, IIb, III devices with AI/ML components face dual conformity assessment obligations under both EU MDR and EU AI Act. Manufacturers must understand how their AI devices are classified under both frameworks.

Nov 27, 2026

Legacy device EUDAMED registration deadline. Devices on the market before May 28, 2026 that will continue to be sold must be registered in EUDAMED by this date or withdrawn from the market.

May 2027

Reusable surgical instruments require UDI on the device label under EU MDR UDI class-specific deadlines.

December 2027

Class III and implantable Class IIb devices must hold valid EU MDR certificates from a Notified Body. With 12-18 month NB backlogs, manufacturers who are not already in the NB queue are at significant risk of missing this deadline.

December 2028

Class IIa and non-implantable Class IIb EU MDR transition complete. All devices in these classes must be certified under EU MDR. Manufacturers missing this deadline cannot legally market these devices in the EU.

Sources: NordMDR (May 2026); FDA.gov; Celegence (December 2025); Arnold and Porter (February 2026); IntuitionLabs (April 2026)

The convergence of QMSR (February 2026), EUDAMED mandatory (May 2026), EU AI Act high-risk obligations (August 2026 through 2027), and the NB certification deadline framework (December 2027/2028) creates the most compressed regulatory compliance calendar the medical device industry has faced in recent history. Each milestone is independently mandatory and independently penalizes non-compliance through market access loss – a missed EUDAMED registration loses EU market access; a missed NB certification deadline removes the ability to continue selling in the EU class affected. global regulatory deadline framework
FDA is expected to release broader guidance on AI/ML-enabled software in late 2026, formalizing requirements for model performance monitoring, bias documentation, and lifecycle management that have been addressed in draft form through the January 2025 draft guidance. Manufacturers developing AI device submissions in 2026 should build lifecycle management documentation that anticipates these forthcoming finalized requirements. IntuitionLabs; Censinet, 2026
The MDSAP (Medical Device Single Audit Program) pathway – covering simultaneous audit recognition by FDA, Health Canada, TGA (Australia), ANVISA (Brazil), and PMDA (Japan) – remains one of the highest-value single investments in global regulatory strategy for manufacturers targeting multiple IMDRF-aligned markets. A single MDSAP audit provides QMS evidence for five major regulatory authorities simultaneously, reducing the total audit burden for manufacturers with multi-jurisdictional market access objectives. MDSAP; global regulatory strategy literature

Key Takeaways for Medical Device Regulatory, Quality, and Commercial Teams

QMSR is live – and FDA inspectors now have access to records they couldn’t request before

The QMSR’s elimination of the 820.180(c) exceptions means that management review records, quality audit reports, and supplier audit reports are now fully accessible to FDA investigators during device manufacturer inspections. Manufacturers who treated these records as internal-only under the QSR must update their inspection readiness posture. Under QMSR, risk-based decision-making must be demonstrably embedded across all QMS processes – not just design controls – and must be provable through documented evidence that can be produced during an inspection.

EUDAMED is mandatory now – and legacy devices have until November 27, 2026

EUDAMED’s May 28, 2026 mandatory date has passed. Every EU economic operator without a valid SRN cannot legally place devices on the EU market, effective immediately. For legacy devices already on the market before May 28, manufacturers have until November 27, 2026 to complete registration – after which unregistered devices must be withdrawn. The EUDAMED supply interruption notification obligation under Article 10a (January 2025) adds a second liability dimension: inaccurate EUDAMED data about supply availability can create double liability for manufacturers.

ISO 13485 now satisfies both FDA QMSR and EU MDR simultaneously – this is the harmonization dividend

QMSR’s incorporation of ISO 13485:2016 by reference creates the first genuine QMS harmonization between the U.S. and EU frameworks. Manufacturers who are ISO 13485 certified and MDSAP-audited hold a QMS evidence package that is simultaneously valid for FDA QMSR compliance, EU MDR quality system requirements, and the QMS requirements of Canada, Australia, Japan, and Brazil. The manufacturers who invested in ISO 13485 and MDSAP before February 2026 are now seeing the harmonization dividend in reduced QMS compliance overhead across multiple jurisdictions simultaneously.

EU notified body backlogs mean the December 2027 Class III deadline is already at risk for unprepared manufacturers

With 12-18 month notified body backlogs for MDR technical file reviews, the arithmetic for Class III and implantable Class IIb manufacturers is straightforward: manufacturers who have not yet submitted to a notified body cannot realistically obtain a certificate by December 2027. Notified body slots are fully booked 12-18 months in advance. The window for entering the notified body queue with a realistic path to December 2027 certification is either already closed or closing. Manufacturers in this position must make an immediate decision between accelerating NB engagement, planning for market withdrawal in the affected device classes, or requesting competent authority extension under any applicable transitional provisions.

AI device strategy requires a PCCP and an EU AI Act classification decision simultaneously

FDA has cleared over 1,000 AI/ML medical devices, with 295 cleared in 2025 alone. Manufacturers pursuing AI device clearances in 2026 should build a Predetermined Change Control Plan (PCCP) into their initial 510(k) submission, specifying anticipated algorithm changes and validation methods – this avoids continuous 510(k) resubmission for model updates. Simultaneously, manufacturers targeting the EU market must classify their AI device under the EU AI Act (high-risk Annex III classification applies to many medical AI devices) and plan for dual conformity assessment under both EU MDR and EU AI Act requirements beginning August 2026. These are not sequential planning decisions – they should be made in parallel during device development.

Regulatory strategy is now a competitive differentiator – not just a compliance function

In a $623 billion global market with 295 AI device clearances in a single year, the manufacturers who achieve clearance fastest, maintain broadest market access, and navigate post-market surveillance most efficiently hold a structural commercial advantage over slower-moving competitors. FDA’s 142-day median AI/ML 510(k) clearance time – with 25% cleared under 90 days – demonstrates that submission quality and pre-submission strategy preparation are the controllable variables that separate fast market access from delayed market access. In the EU, the notified body backlog creates a regulatory moat: manufacturers who have already secured MDR certification are protected from competition by manufacturers who cannot achieve the same certification in time for the 2027-2028 deadlines.

Frequently Asked Questions

What is FDA QMSR and how does it differ from the previous QSR?

The Quality Management System Regulation (QMSR), effective February 2, 2026, replaced FDA’s Quality System Regulation (21 CFR Part 820) by harmonising it with ISO 13485:2016. Manufacturers with an existing ISO 13485 certification have a strong foundation for QMSR compliance. Key additions include explicit risk management requirements aligned with ISO 14971, strengthened software validation requirements, and expanded supplier control obligations.

When did EUDAMED become mandatory and what does it require?

EUDAMED became mandatory for all EU economic operators on May 28, 2026. All manufacturers, authorised representatives, importers, and distributors placing medical devices on the EU market must register in EUDAMED, register their devices, and submit UDI data. Notified bodies are reporting 12 to 18 month backlogs for EU MDR certification, making early registration and proactive engagement critical.

How many AI/ML medical devices has FDA cleared?

FDA has cleared over 1,000 AI/ML-enabled medical devices as of 2026, with 295 cleared in 2025 alone. The majority are in radiology and cardiology. FDA’s proposed rule on Predetermined Change Control Plans (PCCPs) allows manufacturers to update AI/ML algorithms within a pre-approved change framework, removing the need for a new 510(k) submission for each software update.

What market entry sequence do most medical device manufacturers follow?

Most manufacturers use one of three models: US-first, EU-first, or simultaneous. US-first is faster to initial revenue for Class II devices using the 510(k) pathway, but EU MDR’s rigorous clinical evidence requirements mean early EU clinical work strengthens both submissions. Simultaneous entry requires the largest upfront regulatory investment but compresses the total time to full-market access.

What post-market surveillance obligations apply under EU MDR?

EU MDR requires all manufacturers to maintain a Post-Market Surveillance system that proactively collects and analyses real-world device data. Class III and implantable devices must produce a Periodic Safety Update Report annually. Class IIa and IIb devices require a PSUR every two years. Serious incidents must be reported within 15 days, and incidents contributing to death within 2 days.

How does the EU AI Act affect medical device manufacturers?

AI-enabled medical devices are classified as high-risk systems under the EU AI Act. Full high-risk obligations apply from August 2026 for new placements and 2027 for existing devices. Obligations cover risk management, data governance, transparency, human oversight, accuracy, robustness, and cybersecurity. Manufacturers that already comply with EU MDR clinical evaluation requirements have a strong foundation but face additional AI-specific obligations around explainability and bias monitoring.

Which emerging markets are the highest priority for regulatory investment?

China (NMPA), India (CDSCO), Brazil (ANVISA), and Japan (PMDA) represent the highest-priority emerging market regulatory investments for most manufacturers because of market size, regulatory formalisation, and increasing alignment with ISO 13485 and ICH standards. ASEAN’s AMDD harmonisation initiative is creating streamlined pathways across Southeast Asia. Each market has distinct local clinical data requirements, import licensing, and labelling obligations.

Government and Regulatory Sources

FDA / U.S. Regulatory Sources
FDA.gov – QMSR Overview: effective February 2, 2026; ISO 13485:2016 incorporation by reference; new CP 7382.850; withdrawal of QSIT, 7382.845, and 7383.001
FDA QMSR FAQ: no transition grace period; 820.180(c) exceptions removed; management review and audit reports now accessible; PMA/HDE submission compliance requirements
Federal Register December 4, 2025 – QMSR Technical Amendments: 179 CFR sections amended across 18 parts; updating references from QSR to QMSR; APA notice exemption
ComplianceQuest (April 2026) – FDA QMSR 2026: risk-based thinking across all QMS processes; Medical Device File structure; IBR force of law; spreadsheets cannot scale
Alston and Bird (November 2025) – QMSR Transition for PMA/HDE: October 27, 2025 FDA draft guidance; QMS information for PMA submissions; gap identification and risk-based rationale
Morgan Lewis (October 2024) – QMSR Ready? HDE/PMA cutoff; QSR vs QMSR substantial similarity; ISO 13485 transition significance
EU Regulatory Sources
Arnold and Porter (February 2026) – EU Medical Device Shake-Up: EUDAMED transition period; notified body oversight reform December 2025; EU Authorized Representative requirements; some companies reconsidering EU launches; lifecycle regulation
NordMDR (May 2026) – EU MDR Deadlines 2026: EUDAMED May 28, 2026 mandatory; 12-18 month NB backlogs; Class III December 2027 / Class IIa December 2028 deadlines; no grace period; SRN required
Celegence (December 2025) – EUDAMED Mandatory May 2026: Commission Decision EU 2025/2371 published November 27, 2025; four modules functional; six-month transition; Article 10a supply interruption notification; legacy device deadline November 27, 2026
MDX CRO (June 2026) – EUDAMED Mandatory Timelines: UDI/Device registration must be completed before new devices placed on market; 12-month transition for legacy devices; Q1 2026 UDI-DI now mandatory
Arena Solutions (December 2025) – EU UDI Deadlines: $170B European MedTech market (2024); 26.4% global market share; May 28, 2026 new device registration mandatory; November 27, 2026 legacy deadline
QServe Group (February 2026) – EUDAMED at the Tipping Point: Regulation EU 2024/1860; OJEU publication November 27, 2025; four-module validation; vigilance/PMS modules still in development
AI Devices and Market Data
Grand View Research (2026) – AI-Enabled Medical Devices Market: $13.67B (2024) to $255.76B (2033); 38.5% CAGR; North America 52.86%; Asia Pacific 40.84%; software 51.15%; radiology largest therapeutic area
Innolitics (December 2025) – 2025 AI/ML 510(k) Year in Review: 142-day median clearance; 150-day average; 25% cleared under 90 days; radiology dominance; PCCP in 10% of submissions
Censinet (June 2026) – AI Medical Devices FDA Approval Process: 1,000+ cleared through early 2026; 95-97% via 510(k); January 2025 draft guidance; PCCP mechanism explained
IntuitionLabs (March 2026) – FDA AI Medical Device Tracker: 295 authorizations in 2025; radiology share declining from 79% to 56%; PCCPs in 10% of submissions; ~5% adverse event reporting by mid-2025
Toward Healthcare (May 2026) – Global Medical Devices Market: $623.37B in 2026; $1.08T by 2035 at 6.34% CAGR; GE HealthCare 100 AI authorizations; ~1,000 AI devices from 1995 to August 2024
Market Research Future (2026) – Medical Devices Market: $688.18B in 2025; $1.38T by 2035; J&J $15B+ annual R&D; Siemens Healthineers/Philips partnership March 2025